Cargando…
Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
Metastatic castration-resistant prostate cancer (mCRPC) is the ultimately lethal form of prostate cancer. Docetaxel chemotherapy was the first life-prolonging treatment for mCRPC; however, the standard maximally tolerated dose (MTD) docetaxel regimen is often not considered for patients with mCRPC w...
Autores principales: | Parshad, Shruti, Sidhu, Amanjot K., Khan, Nabeeha, Naoum, Andrew, Emmenegger, Urban |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147851/ https://www.ncbi.nlm.nih.gov/pubmed/35628909 http://dx.doi.org/10.3390/jcm11102783 |
Ejemplares similares
-
Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
por: Sidhu, Amanjot, et al.
Publicado: (2023) -
Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022) -
Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer
por: Briones, Juan, et al.
Publicado: (2021) -
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017) -
Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)